Gaucher's disease type III is a rare inherited condition where the body cannot properly break down fatty substances, leading to progressive problems affecting the brain, bones, and major organs throughout life.
Gaucher disease type 3, Chronic neuronopathic Gaucher disease, Gaucher disease subacute neuronopathic type, Cerebral juvenile and adult form of Gaucher disease, Subacute neuronopathic Gaucher's disease
E75.2 5C56.0Y 10075699
What is Gaucher's Disease Type III
Gaucher's disease type III is an inherited disorder that affects how the body breaks down fatty substances. The disease is caused by a lack of a special protein called an enzyme, which is a substance that helps the body perform important chemical processes. In this case, the missing enzyme is called glucocerebrosidase, which normally helps break down fatty materials in cells.
When this enzyme does not work properly, fatty substances build up inside cells throughout the body, particularly in the liver, spleen, bone marrow, and brain. These fatty deposits cause the cells to swell and stop working normally, leading to a wide range of health problems.
Gaucher's disease type III is one of three main forms of the disease. Unlike type 1, which does not affect the brain, type III causes brain involvement along with problems in other organs and bones. Compared to type 2, which appears very early in infancy and progresses rapidly, type III develops more gradually and people with this form may survive into adulthood.
Brain (central nervous system)
Spleen
Liver
Bone marrow
Bones
Lungs
Heart
Kidneys
How Common Is It
Gaucher's disease type III is the most common form of the disease worldwide, though it remains rare in the United States. It accounts for about 5% of all Gaucher disease cases.
The disease is more frequently seen in certain regions and populations. It is more common than type 1 in the Middle East, India, China, and the Pacific Rim. The symptoms and severity of type III can vary greatly even within the same region. For example, the way the disease appears in Egypt, China, and Sweden differs so much that it may not even seem like the same condition.
Overall, Gaucher disease affects approximately 1 in 50,000 to 1 in 100,000 people in the general population, with type III being less common than type 1 in Western countries but more prevalent globally.
What Causes This Disease
Gaucher's disease type III is caused by changes in a gene called GBA, which is located on chromosome 1. This gene contains instructions for making the enzyme glucocerebrosidase. When the gene has a mutation (a change in its genetic code), the body cannot produce enough working enzyme.
The disease is inherited in an autosomal recessive pattern. This means a person must inherit two copies of the mutated gene—one from each parent—to develop the disease. People who inherit only one mutated gene are called carriers and typically do not have symptoms.
Scientists have identified about 50 different mutations in the GBA gene that are linked to type III. The most common mutation is called L444P (also known as L483P). This particular mutation usually causes problems in organs and bones first, with brain-related symptoms appearing later.
The severity of symptoms can vary greatly even among people with the same genetic mutation. Researchers believe that other genes and factors, including ethnic background, may influence how the disease develops and how serious it becomes.
Signs and Symptoms
The symptoms of Gaucher's disease type III vary widely from person to person. The disease has a later start and slower progression compared to type 2. Brain-related problems appear in childhood or teenage years, which is much later than in type 2 but earlier than the typical age range for other symptoms.
Some people have only mild organ involvement along with eye movement problems as their only brain-related symptom. Others develop more severe brain problems that get worse over time.
Brain and Nervous System Problems
All people with type III eventually develop some degree of brain involvement. One of the most consistent features is difficulty moving the eyes from side to side, called supranuclear horizontal ophthalmoplegia.
Other brain-related symptoms may include:
Seizures, including a specific type called progressive myoclonic epilepsy
Problems with balance and coordination (cerebellar ataxia)
Stiff or jerky movements (spasticity)
Difficulty thinking and memory problems (cognitive impairment and dementia)
Tremors
Difficulty processing new information
Organ Problems
The spleen and liver become greatly enlarged as fatty substances build up in them. This causes the belly to become swollen and may lead to discomfort or pain. An enlarged spleen can also trap and destroy blood cells, leading to additional problems.
The lungs, heart, and kidneys may also be affected, though this is less common and rarely causes obvious symptoms.
Blood Problems
Many people with type III develop pancytopenia, which means low levels of multiple types of blood cells:
Thrombocytopenia (low platelet count) can be severe and causes easy bruising and bleeding
Anemia (low red blood cell count) leads to tiredness and weakness
Low white blood cell count (less common) can affect the immune system
Bone Problems
Bone involvement is a significant feature of type III and may cause:
Bone pain
Bone deformities
Osteopenia (weakened bones), which can lead to fractures even without obvious injury
Compression of the spine
Death of bone tissue (aseptic osteonecrosis)
Skeletal irregularities
Other Symptoms
People with type III may also experience:
Severe fatigue
Slow growth in children
Delayed puberty
Respiratory problems
Poor coordination
Difficulty shifting gaze and tracking objects with the eyes
How Is It Diagnosed
Diagnosing Gaucher's disease type III involves several steps. Doctors typically start by asking about symptoms and family medical history, then perform a physical examination to check for enlarged organs, bone problems, and signs of brain involvement.
Blood Tests
Blood samples can be tested to measure the level of glucocerebrosidase enzyme activity. Low enzyme levels suggest Gaucher disease. Blood tests can also check for certain markers that increase in Gaucher disease, such as chitotriosidase, angiotensin converting enzyme, ferritin, and tartrate-resistant acid phosphatase.
Genetic Testing
Genetic analysis can identify specific mutations in the GBA gene. This testing confirms the diagnosis and can help predict the course of the disease, though it cannot always accurately predict how severe symptoms will be.
Imaging Tests
Various imaging tests help doctors see how the disease affects different organs and bones:
Ultrasound or MRI scans check the size of the spleen and liver
X-rays look for bone damage and complications
Bone scintigraphy (a special type of scan) detects bone problems
Osteodensitometry measures bone density in the spine and hip
Heart ultrasound checks for pulmonary arterial hypertension
Physical Examination
Doctors check movement, coordination, and reflexes to assess brain and nervous system involvement. They may also examine the skin for signs of bruising and measure growth in children.
Treatment Options
There is currently no cure for Gaucher's disease type III, but treatments can help manage many of the symptoms, particularly those not involving the brain.
Enzyme Replacement Therapy
Enzyme replacement therapy (ERT) provides an artificial version of the missing enzyme through regular infusions. People with type III can receive ERT to address organ enlargement, bone problems, and blood issues. The treatment is given through an intravenous (IV) line about every two weeks, either at an infusion center or at home.
Three FDA-approved medications are available for ERT:
Cerezyme® (imiglucerase)
VPRIV® (velaglucerase alfa)
Elelyso® (taliglucerase alfa)
ERT works well for controlling complications in organs, bones, and blood. However, the replacement enzyme cannot cross the "blood-brain barrier," which is a protective filter that keeps certain substances out of the brain. This means ERT has little to no effect on brain-related symptoms.
Substrate Reduction Therapy
Substrate reduction therapy (SRT) works differently from ERT. Instead of replacing the missing enzyme, SRT reduces the amount of fatty substances the body produces. This gives the body's own enzyme less work to do. SRT medications are taken by mouth rather than by infusion.
Two FDA-approved oral medications are available:
Cerdelga® (eliglustat)
Zavesca® (miglustat)
These medications are not approved for everyone. They cannot be used in people under 18 or women who are breastfeeding, pregnant, or trying to become pregnant.
Treatment of Symptoms
In addition to ERT or SRT, doctors may recommend other treatments to manage specific symptoms:
Pain medications for bone pain
Physical therapy to help with movement and coordination
Nutritional supplements to support bone health
Treatment for seizures if they occur
Current Limitations
The most significant challenge in treating type III is that current therapies cannot effectively treat the brain involvement that characterizes this form of the disease. Researchers continue to work on new approaches, including treatments that might be able to reach the brain.
Living with the Disease
People with Gaucher's disease type III may survive into adulthood, though the disease affects everyone differently. With proper treatment and monitoring, many can manage their symptoms and maintain a reasonable quality of life.
Regular Medical Care
Working with a specialist experienced in treating Gaucher disease is essential. Regular check-ups help track the disease's progress and adjust treatment as needed. Many people need to see their specialist only once a year, though more frequent visits may be necessary depending on symptoms.
Specialists monitor important health indicators such as spleen and liver size, bone density, and blood counts. They also help define treatment goals and track progress toward achieving them.
Daily Life Adjustments
Managing energy is important for people with type III, as fatigue is a common symptom. Strategies include scheduling breaks throughout the day, breaking tasks into smaller parts, and working on challenging activities when feeling most rested. Some people find it helpful to think of their energy in units, planning their day to conserve energy when needed.
Physical activity helps support bone and joint health, but people with type III should consult their doctor and physical therapist before starting an exercise program. Walking, swimming, strength training, stretching, yoga, and tai-chi may be suggested. High-impact exercises should typically be avoided because of the increased risk of bone fractures.
Impact on Daily Activities
The disease can significantly affect daily life. Motor problems and brain-related symptoms become more noticeable with age. Common challenges include:
Difficulty working or performing well at school
Limited ability to participate in social and family activities
Problems with mobility, including walking, driving, and using public transportation
Decreasing independence over time
Support and Resources
Connecting with others who have the disease and their families can provide valuable emotional support and practical advice. Support groups, both in-person and online, offer opportunities to share experiences and learn from others facing similar challenges.
Building a comprehensive care team that may include geneticists, hematologists, orthopedists, liver specialists, and other healthcare providers helps address the many different aspects of the disease.
info This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Finland
